Naltrexone + bupropion

Naltrexone + bupropion has been studied in 46 papers since 2022: 2 trials and 11 observational studies in people, 1 in animals, 31 reviews; 24 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.

InterventionApproved 2014

46 papers study it13 more mention it11 findingsUpdated

PubChemPubChemChEBIChEBI

4 new papers in 30 daysSee all 59 papers on naltrexone + bupropion

At a glance

Independent labs found the same change in people. 5 independent labs in 4 countries; 31 trials, none about aging, 6 with no results posted.

“56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003)”
Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled AnalysisObesity (Silver Spring, Md.)2026doi:10.1002/oby.70183

None of its findings points the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 5 independent labs in 4 countries
  • 31 trials, none about aging, 6 with no results posted
  • Funders: Centro de Investigación en Red en Enfermedades Cardiovasculares and 6 more
  • 5 of 10 findings with company ties
  • 11 of 31 trials sponsored by its developers
  • Human trial2
  • Humans11
  • Animals1
  • In silico1

Studies in people

1 study gave naltrexone + bupropion to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weight5.7% ± 0.6% vs 2.7% ± 0.8%

no change: Has no effect on psychiatric adverse events27.5% vs 22.1%

Review of trials56 weeks511 people pooled87% were femaleParticipants with baseline symptoms of depressionObesity (Silver Spring, Md.), Mar 31, 2026

What did studies of naltrexone + bupropion find?

5

Studies of naltrexone + bupropion measured 5 outcomes; the most studied is body weight (3 studies).

Body weight

downin humans2downin reviews1−6% loss of starting total body weight

3 studies
  1. Naltrexone + bupropion decreases body weight in humans (5.7% ± 0.6% vs 2.7% ± 0.8%).

    “From baseline to Week 56, participants assigned to NB‐ER had a significantly greater mean (±SE) percent reduction in body weight of 5.7% ± 0.6% (95% CI: 4.6%–6.9%) compared to the 2.7% ± 0.8% (95% CI: 1.1%–4.4%) reduction in the placebo group”

    Human trial56 weeksn = 511

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    Obesity (Silver Spring, Md.)

  2. Naltrexone + bupropion decreases body weight in humans (overweight/obesity and mild to moderate symptoms of depression) (5.7% ± 0.6% vs. 2.7% ± 0.8%).

    “56-week weight loss was significantly greater with NB-ER (5.7% ± 0.6%) than with placebo (2.7% ± 0.8%; p = 0.003)”

    Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    Obesity (Silver Spring, Md.)

  3. Naltrexone + bupropion decreases body weight in humans (-5.60 [-8.64 to -2.56] kg).

    “Naltrexone-bupropion, GLP-1 receptor agonists, SGLT-2 inhibitors, and metformin were found to reduce body weight (-5.60 [-8.64 to -2.56] kg”

    Review

    Efficacy of Weight-Lowering Agents on Fat Distribution: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

    Obesity reviews : an official journal of the International Association for the Study of Obesity

  4. Naltrexone + bupropion decreases body weight (~6% loss of starting total body weight).

    “Clinical trials report ~ 6% loss of starting total body weight with use of Contrave”

    Review

    Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review

    Reproductive biology and endocrinology : RB&E

Psychiatric adverse events

no changein humans1

1 study
  1. Naltrexone + bupropion showed no clear effect on psychiatric adverse events in humans (27.5% vs 22.1%).

    “PAEs occurred in 27.5% of participants treated with NB‐ER and 22.1% of those treated with placebo, with no significant difference between the groups in overall incidence.”

    Human trial56 weeksn = 511

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    Obesity (Silver Spring, Md.)

  2. Naltrexone + bupropion showed no clear effect on psychiatric adverse events in humans (overweight/obesity and mild to moderate symptoms of depression) (27.5% vs. 22.1%).

    “NB-ER and placebo did not differ in safety signals including PAE occurrence (27.5% NB-ER vs. 22.1% placebo), depressive symptom increases (9.5% NB-ER vs. 8.8% placebo), or suicidal ideation (1.8% NB-ER vs. 2.0% placebo).”

    Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    Obesity (Silver Spring, Md.)

Depression

no changein humans1

1 study
  1. Naltrexone + bupropion showed no clear effect on depression in humans (overweight/obesity and mild to moderate symptoms of depression) (-7.1 ± 0.4 vs. -6.7 ± 0.5).

    “Participants experienced clinically meaningful improvements in depression of -7.1 ± 0.4 with NB-ER and -6.7 ± 0.5 with placebo, with no significant differences between the groups.”

    Human trialoverweight/obesity and mild to moderate symptoms of depressionextended-release56 weeks

    Use of Naltrexone-Bupropion in Persons With Overweight/Obesity and Symptoms of Depression: A Pooled Analysis

    Obesity (Silver Spring, Md.)

More on Depression

Emotional eating

downin humans1

1 study
  1. Naltrexone + bupropion is linked with lower emotional eating in humans (early responders (≥5% weight loss at 3 months)) (dz 2.04).

    “emotional eating reductions with naltrexone/bupropion (dz 2.04)”

    Humansearly responders (≥5% weight loss at 3 months)6 months

    Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice

    Preprints.orgPreprint

Ki67

no changein rats1

1 study
  1. Naltrexone + bupropion showed no clear effect on Ki67 in rats (obese type 2 diabetes).

    “while NTX + BUP showed insignificant effects.”

    Animalsobese type 2 diabetesorally4 mg/45 mg /kg/daymales

    Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1

    Journal of molecular histology

More on Ki67

What is naltrexone + bupropion linked with?

2

Studies link naltrexone + bupropion with 2 measures: suicide attempt and suicidal ideation.

Suicide attempt

upin humans1

1 study
  1. Naltrexone + bupropion is associated with suicide attempt in humans (disproportionality analysis of FAERS reports) (ROR 4.11 (95% CI 1.62-10.45)).

    “Naltrexone/bupropion showed elevated disproportional reporting for suicidal ideation (ROR 3.84; 95% CI 2.89-5.12) and suicide attempt (ROR 4.11; 95% CI 1.62-10.45.”

    Humansdisproportionality analysis of FAERS reports

    Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System

    International journal of clinical pharmacy

Suicidal ideation

upin humans1

1 study
  1. Naltrexone + bupropion is associated with suicidal ideation in humans (disproportionality analysis of FAERS reports) (ROR 3.84 (95% CI 2.89-5.12)).

    “Naltrexone/bupropion showed elevated disproportional reporting for suicidal ideation (ROR 3.84; 95% CI 2.89-5.12) and suicide attempt (ROR 4.11; 95% CI 1.62-10.45.”

    Humansdisproportionality analysis of FAERS reports

    Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System

    International journal of clinical pharmacy

Has naltrexone + bupropion been tested in people?

0 of 31 about aging

Yes: 2 trials and 11 observational studies in people have been published, and 31 trials are registered.

Approved

Repurposing

All 16

In trials

  • Cigarette smoking

    Phase 4Results posted1 trial

  • Heart repolarization

    Phase 1Completed1 trial

Stopped

  • NCT04531176TerminatedObesity

    After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.

  • NCT03132571TerminatedDiabetes mellitus

    Study discontinued due to funding.

  • NCT06374290TerminatedSmoking cessation

    Unable to recruit eligible participants and expiration of study medication.

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 6Mar 2026: 4Apr 2026: 0May 2026: 2Jun 2026: 2Jul 2026: 0Aug 2026: 0Sep 2026: 2Oct 2026: 4Nov 2026: 128 papers in 12 months

See all 59 papers on naltrexone + bupropion